In vitro, NKp46/CD16A/CD19-NKCE, a NK cell engager with CD16A on the surface of NKs binding NKp46 and CD19 highly expressed on the surface of B-cell ALL cells, enhanced the activation of NKs and promoted NK cell-mediated lytic effects against pediatric BCP ALL (Figure 1) (146). This evidence concerns the gene NCR1 and acute lymphoblastic leukemia.